Last reviewed 2026-04-20 · How we verify

Temovate (CLOBETASOL PROPIONATE)

Temovate (Clobetasol Propionate) is a corticosteroid medication developed by Fougera Pharms, targeting the glucocorticoid receptor to treat various inflammatory skin conditions. It is a small molecule modality, FDA-approved in 1985 for conditions such as atopic dermatitis, contact dermatitis, and plaque psoriasis. As an off-patent medication, Temovate is available from multiple generic manufacturers. Key safety considerations include potential skin irritation and allergic reactions. Temovate is a topical corticosteroid, applied directly to the affected skin area.

At a glance

Approved indications

• Atopic dermatitis
• Contact dermatitis
• Dermatosis of scalp
• Inflammatory dermatosis
• Nummular eczema
• Plaque psoriasis
• Scalp psoriasis
• Seborrheic dermatitis

Common side effects

• burning sensation
• irritation
• itching

Key clinical trials

• Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
• Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
• Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
• Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo (EARLY_PHASE1)
• Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid (PHASE4)
• Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus. (NA)
• The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.